LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    EuropaBio draft response to the IIA on European Health Data Space

    04/02/2021
    FEEDBACK

    EuropaBio draft response to the IIA on European Health Data Space

    EuropaBio welcomes the European Commission’s plan to begin a discussion with stakeholders to develop the EHDS. Science is evolving fast and digital tools are accelerating our ability to conduct research. For the biotechnology industry, it is imperative quality data sets are collected and analysed, while protecting privacy and maintaining trust in how the data are used.

    This initiative is an opportunity to accelerate innovations that will optimise diagnostic and treatments, increasing cost-effectiveness of healthcare systems. The EC should work with the MSs to develop/harmonise the infrastructures required to make this feasible. While the EHDS would enable sharing data among research organizations within the EU, this should not distract from also developing ways to effectively share such data with research organizations internationally. The success of the EHDS should be measured on its capacity to increase the competitiveness in the EU health sector and to create health innovations to the benefit of researchers, healthcare professionals and citizens.

    Objective 1: Ensuring access, sharing and use of health data for healthcare delivery purposes
    Access/exchange of health data for research, including secondary use health data, is today too limited in the EU. EuropaBio supports the intention to reduce fragmentation of legislation through introducing a governance framework to clarify the rules across the EU with regards to collecting, accessing, and analysing health data. As a research-based industry with a history of handling patient data, access to such quality data would accelerate the sector’s ability to develop innovations in diagnostics and therapeutics.

    Interoperable data infrastructures should be developed. The value of such a network lies in the participation of all MSs and their ability to create such infrastructures. It will be equally important that all MSs, supported by the EC, maintain these to a common standard, including through appropriate funding mechanisms and sharing of relevant expertise. It will also be important to ensure local HCPs, as a key part of the system, are also trained on the harmonised system for entering and reading the data.

    Furthermore, patient trust in sharing their data is key to the success of any initiative to harness data for healthcare purposes and research. Citizens must be assured their data is protected and only used for purposes within the principle of data altruism. Patients should remain owners of their data, and research entities should remain the owners of the data resulting from their research.

    Objective 2: Fostering a genuine single market in digital health covering digital health services
    Digital health services are an essential part of the Digital Single Market. Improved access to digital health services and products, including tele-health and mHealth, have the potential to greatly improve access to healthcare and patient ability to manage their own health. Other key initiatives, such as cross-border healthcare, are enabled by such digital infrastructures.

    Objective 3: Enhancing the development, deployment, and application of trustworthy digital health products and services, including those incorporating AI in the field of health
    The adoption of digital technologies in health, in particular AI, will play a critical role on how healthcare is delivered in the future. it will support process efficiencies, and help overcome staff shortages. Telemedicine can provide health expertise to remote areas of the EU, which may be distant from specialised HCPs or centres of excellence but can also serve in situations of emergency and, in general, simplify patients’ lives by avoiding unnecessary movements, speed up time to diagnoses and make available expertise.

    In conclusion, EuropaBio is ready to serve as a constructive partner in exploring all options and co-designing a framework to ensure we can harness the data revolution in the interest of citizens, society, and the economy.

    Download the file below to read the full feedback.

    EuropaBio draft response to the IIA on European Health Data Space


    Download
    2021_02_H_O_EuropaBio-draft-response-to-the-IIA-on-European-Health-Data-SpaceDownload
    Share
    Communications Team
    Communications Team

    Related posts

    18/05/2026

    Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force


    Read more
    12/05/2026

    ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act


    Read more
    08/05/2026

    Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology


    Read more

    Important links

    • Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force
    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.